{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:13:03Z","timestamp":1788487983460,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00865-6","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:48:22Z","timestamp":1782154102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors do not increase cognitive risk"],"prefix":"10.1186","volume":"21","author":[{"given":"Dongsheng","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8512-8902","authenticated-orcid":false,"given":"Guoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"2","key":"865_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537\u201357. https:\/\/doi.org\/10.1210\/er.2018-00184.","journal-title":"Endocr Rev"},{"issue":"9","key":"865_CR2","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamacardio.2024.1712","volume":"9","author":"CP Benziger","year":"2024","unstructured":"Benziger CP, Stebbins A, Wruck LM, Effron MB, Marquis-Gravel G, Farrehi PM, et al. Aspirin dosing for secondary prevention of atherosclerotic cardiovascular disease in male and female patients: a secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiol. 2024;9(9):808\u201316. https:\/\/doi.org\/10.1001\/jamacardio.2024.1712.","journal-title":"JAMA Cardiol"},{"key":"865_CR3","doi-asserted-by":"publisher","unstructured":"Williams MS, Levine GN, Kalra D, Agarwala A, Baptiste D, Cigarroa JE, et al. 2025 AHA\/ACC clinical performance and quality measures for patients with chronic coronary disease: a report of the American college of Cardiology\/American heart association joint Committee on performance measures. Circ: Cardiovasc Qual Outcomes, 2025: 2025;18(6):S0735\u20131097(25)282\u20137. https:\/\/doi.org\/10.1161\/HCQ.0000000000000140.","DOI":"10.1161\/HCQ.0000000000000140"},{"issue":"36","key":"865_CR4","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024, 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"key":"865_CR5","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation 2019, 2018;139:e1046\u201381. https:\/\/doi.org\/10.1161\/CIR.0000000000000624.","DOI":"10.1161\/CIR.0000000000000624"},{"issue":"5","key":"865_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/gerona\/glq026","volume":"65A","author":"G Zuliani","year":"2010","unstructured":"Zuliani G, Cavalieri M, Galvani M, Volpato S, Cherubini A, Bandinelli S, et al. Relationship between Low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J Geron Biol Sci Med Sci. 2010;65A(5):559\u201364. https:\/\/doi.org\/10.1093\/gerona\/glq026.","journal-title":"J Geron Biol Sci Med Sci"},{"issue":"5","key":"865_CR7","first-page":"320","volume":"6","author":"J-M Kim","year":"2002","unstructured":"Kim J-M, Stewart R, Shin I-S, Yoon J-S. Low cholesterol, cognitive function and alzheimer s disease in a community population with cognitive impairment. J Nutr Health Aging. 2002;6(5):320\u201323.","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"865_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804\u201314. https:\/\/doi.org\/10.1093\/eurjpc\/zwab208.","journal-title":"Eur J Prev Cardiol"},{"key":"865_CR9","doi-asserted-by":"publisher","unstructured":"Rajan KB, Mcaninch EA, Wilson RS, Dhana A, Evans-Lacko S, Evans DA. Statin initiation and risk of incident alzheimer disease and cognitive decline in genetically susceptible older adults. Neurology. 2024;102(7):e209168. https:\/\/doi.org\/10.1212\/WNL.0000000000209168.","DOI":"10.1212\/WNL.0000000000209168"},{"issue":"8","key":"865_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00002018-200730080-00003","volume":"30","author":"BA Golomb","year":"2007","unstructured":"Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects. Drug Saf. 2007;30(8):669\u201375. https:\/\/doi.org\/10.2165\/00002018-200730080-00003.","journal-title":"Drug Saf"},{"issue":"16","key":"865_CR11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u201309. https:\/\/doi.org\/10.1056\/NEJMoa1500858.","journal-title":"N Engl J Med"},{"issue":"7","key":"865_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1701131.","journal-title":"N Engl J Med"},{"issue":"27","key":"865_CR13","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","volume":"45","author":"AD Sniderman","year":"2024","unstructured":"Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non\u2013high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410\u201318. https:\/\/doi.org\/10.1093\/eurheartj\/ehae258.","journal-title":"Eur Heart J"},{"issue":"23","key":"865_CR14","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","volume":"83","author":"CDL Johannesen","year":"2024","unstructured":"Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. JACC. 2024;83(23):2262\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.423.","journal-title":"JACC"},{"issue":"5","key":"865_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/alz.12442","volume":"18","author":"C Picard","year":"2022","unstructured":"Picard C, Nilsson N, Labont\u00e9 A, Auld D, Rosa-Neto P, Ashton NJ, et al. \u2009Apolipoprotein B is a novel marker for \u2009early tau pathology in \u2009Alzheimer\u2019s disease. \u2009Alzheimers & Dementia. \u20092022;18(5):875\u201387. https:\/\/doi.org\/10.1002\/alz.12442.","journal-title":"Alzheimers & Dementia"},{"issue":"10","key":"865_CR16","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.neurobiolaging.2013.04.008","volume":"34","author":"T L\u00f6ffler","year":"2013","unstructured":"L\u00f6ffler T, Flunkert S, Havas D, S\u00e1ntha M, Hutter-Paier B, Steyrer E, et al. Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAppsl mice. Neurobiol Aging. 2013;34(10):2379\u201388. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.04.008.","journal-title":"Neurobiol Aging"},{"key":"865_CR17","doi-asserted-by":"publisher","first-page":"102149","DOI":"10.1016\/j.arr.2023.102149","volume":"93","author":"J De Oliveira","year":"2024","unstructured":"De Oliveira J, Moreira ELG, De Bem AF. Beyond cardiovascular risk: implications of familial hypercholesterolemia on cognition and brain function. Ageing Res Rev. 2024;93:102149. https:\/\/doi.org\/10.1016\/j.arr.2023.102149.","journal-title":"Ageing Res Rev"},{"key":"865_CR18","doi-asserted-by":"publisher","unstructured":"Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pe\u00f1a JM, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the national lipid association. J Clin Lipidol. 2024;18(5):e647\u201363. https:\/\/doi.org\/10.1016\/j.jacl.2024.08.013.","DOI":"10.1016\/j.jacl.2024.08.013"},{"issue":"1","key":"865_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-024-00432-x","volume":"13","author":"E Liu","year":"2024","unstructured":"Liu E, Zhang Y, Wang J-Z. Updates in Alzheimer\u2019s disease: from basic research to diagnosis and therapies. Transl Neurodegener. 2024;13(1):45. https:\/\/doi.org\/10.1186\/s40035-024-00432-x.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"865_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","volume":"25","author":"C Parra Bravo","year":"2024","unstructured":"Parra Bravo C, Naguib SA, Gan L. Cellular and pathological functions of tau. Nat Rev Mol Cell Biol. 2024;25(11):845\u201364. https:\/\/doi.org\/10.1038\/s41580-024-00753-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"865_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1601-183X.2006.00221.x","volume":"6","author":"RS Reiserer","year":"2007","unstructured":"Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe + PSEN1\u0394E9 bigenic mouse model of alzheimer\u2019s disease. Genes Brain Behav. 2007;6(1):54\u201365. https:\/\/doi.org\/10.1111\/j.1601-183X.2006.00221.x.","journal-title":"Genes Brain Behav"},{"issue":"9","key":"865_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2008.132","volume":"9","author":"MC Jonas","year":"2008","unstructured":"Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 2008;9(9):916\u201322. https:\/\/doi.org\/10.1038\/embor.2008.132.","journal-title":"EMBO Rep"},{"key":"865_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbi.2023.11.008","volume":"115","author":"A Vilella","year":"2024","unstructured":"Vilella A, Bodria M, Papotti B, Zanotti I, Zimetti F, Remaggi G, et al. PCSK9 ablation attenuates a\u03b2 pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice. Brain Behav Immun. 2024;115:517\u201334. https:\/\/doi.org\/10.1016\/j.bbi.2023.11.008.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"865_CR24","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI117915","volume":"95","author":"DA Purcell-Huynh","year":"1995","unstructured":"Purcell-Huynh DA, Farese RV, Johnson DF, Flynn LM, Pierotti V, Newland DL, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 1995;95(5):2246\u201357. https:\/\/doi.org\/10.1172\/JCI117915.","journal-title":"J. Clin. Invest"},{"issue":"13","key":"865_CR25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.2174\/1381612826666200218101818","volume":"26","author":"ME T\u00f3th","year":"2020","unstructured":"T\u00f3th ME, Dukay B, Hoyk Z, S\u00e1ntha M. Cerebrovascular changes and neurodegeneration related to hyperlipidemia: characteristics of the human ApoB-100 transgenic mice. CPD. 2020;26(13):1486\u201394. https:\/\/doi.org\/10.2174\/1381612826666200218101818.","journal-title":"CPD"},{"issue":"1","key":"865_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jacasi.2021.04.001","volume":"1","author":"Y-X Cao","year":"2021","unstructured":"Cao Y-X, Sun D, Liu H-H, Jin J-L, Li S, Guo Y-L, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC: Asia. 2021;1(1):82\u201389. https:\/\/doi.org\/10.1016\/j.jacasi.2021.04.001.","journal-title":"JACC: Asia"},{"issue":"1","key":"865_CR27","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","volume":"3","author":"JC Defesche","year":"2017","unstructured":"Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3(1):17093. https:\/\/doi.org\/10.1038\/nrdp.2017.93.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"865_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eprac.2024.09.016","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, et al. American association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025;31:236\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2024.09.016.","journal-title":"Pharmacoepidemiol Drug"},{"issue":"7982","key":"865_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/CIRCULATIONAHA.124.072336","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Guan Y, Liu X, Yang Z, Zhu X, Liu M, Du M, et al. PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Circulation. 2025;151:1512\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072336.","journal-title":"Nature"},{"issue":"7944","key":"865_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jacc.2022.05.041","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol. 2022;80:653\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2022.05.041.","journal-title":"Nature"},{"key":"865_CR31","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa1615664","volume":"20","author":"FJ Boehm","year":"2022","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"Comput Struct Biotechnol J"},{"issue":"5","key":"865_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jacl.2018.05.012","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Mannarino MR, Sahebkar A, Bianconi V, Serban M-C, Banach M, Pirro M. PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results? J Clin Lipidol. 2018;12:1123\u201332. https:\/\/doi.org\/10.1016\/j.jacl.2018.05.012.","journal-title":"Nat Genet"},{"issue":"5","key":"865_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fphar.2022.894685","volume":"32","author":"S Burgess","year":"2017","unstructured":"Feng Z, Li X, Tong WK, He Q, Zhu X, Xiang X, et al. Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS. Front Pharmacol. 2022;13:894685. https:\/\/doi.org\/10.3389\/fphar.2022.894685.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"865_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.jacc.2024.03.382","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An \u201cinclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83:1939\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.382.","journal-title":"Int J Epidemiol"},{"key":"865_CR35","doi-asserted-by":"publisher","unstructured":"Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82:2251\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.007.","DOI":"10.1016\/j.jacc.2023.10.007"},{"issue":"15","key":"865_CR36","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.cjca.2021.03.016","volume":"29","author":"Y Jia","year":"2022","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","journal-title":"Eur J Prev Cardiol"},{"issue":"21","key":"865_CR37","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/pds.677","volume":"34","author":"FD Greco","year":"2015","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Stat Med"},{"issue":"2","key":"865_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-023-06563-x","volume":"44","author":"J Bowden","year":"2015","unstructured":"Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622:348\u201358. https:\/\/doi.org\/10.1038\/s41586-023-06563-x.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"865_CR39","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41586-022-05473-8","volume":"80","author":"DB Rosoff","year":"2022","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318. https:\/\/doi.org\/10.1038\/s41586-022-05473-8.","journal-title":"J Am Coll Cardiol"},{"key":"865_CR40","doi-asserted-by":"publisher","first-page":"1269291","DOI":"10.1016\/j.csbj.2022.05.015","volume":"14","author":"H Li","year":"2023","unstructured":"Boehm FJ, Zhou X. Statistical methods for mendelian randomization in genome-wide association studies: a review. Comput Struct Biotechnol J. 2022;20:2338\u201351. https:\/\/doi.org\/10.1016\/j.csbj.2022.05.015.","journal-title":"Front Genet"},{"key":"865_CR41","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1038\/s41588-018-0099-7","volume":"96","author":"D Ni","year":"2025","unstructured":"Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693\u20138. https:\/\/doi.org\/10.1038\/s41588-018-0099-7.","journal-title":"Mol Metab"},{"issue":"4","key":"865_CR42","doi-asserted-by":"publisher","first-page":"1900739","DOI":"10.1007\/s10654-017-0276-5","volume":"7","author":"C Liu","year":"2020","unstructured":"Burgess S, Thompson SG. Erratum to: interpreting findings from mendelian randomization using the MR-egger method. Eur J Epidemiol. 2017;32:391\u20132. https:\/\/doi.org\/10.1007\/s10654-017-0276-5.","journal-title":"Adv Sci"},{"key":"865_CR43","doi-asserted-by":"publisher","unstructured":"Yavorska OO, Burgess S. MendelianRandomization: an R package for performing mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46:1734\u20139. https:\/\/doi.org\/10.1093\/ije\/dyx034.","DOI":"10.1093\/ije\/dyx034"},{"key":"865_CR44","doi-asserted-by":"publisher","unstructured":"Lu Y, Tang H, Huang P, Wang J, Deng P, Li Y, Zheng J, Weng L. Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study. Int J Epidemiol. 2022;10;51(4):1204-1218. https:\/\/doi.org\/10.1093\/ije\/dyac025.","DOI":"10.1093\/ije\/dyac025"},{"issue":"2","key":"865_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/eurjpc\/zwac123","volume":"31","author":"SB Patel","year":"2025","unstructured":"Jia Y, Guo D, Sun L, Shi M, Zhang K, Yang P, et al. Self-reported daytime napping, daytime sleepiness, and other sleep phenotypes in the development of cardiometabolic diseases: a mendelian randomization study. Eur J Prev Cardiol. 2022;29:1982\u201391. https:\/\/doi.org\/10.1093\/eurjpc\/zwac123.","journal-title":"Endocr Pract"},{"issue":"21","key":"865_CR46","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/sim.6522","volume":"151","author":"Y Guan","year":"2025","unstructured":"Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34:2926\u201340. https:\/\/doi.org\/10.1002\/sim.6522.","journal-title":"Circulation"},{"issue":"18","key":"865_CR47","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/ije\/dyv080","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44:512\u201325. https:\/\/doi.org\/10.1093\/ije\/dyv080.","journal-title":"N Engl J Med"},{"issue":"5","key":"865_CR48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fgene.2023.1269291","volume":"12","author":"MR Mannarino","year":"2018","unstructured":"Li H, Zhang L, Yang F, Feng X, Fu R, Zhao R, et al. Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target mendelian randomization study. Front Genet. 2023;14:1269291. https:\/\/doi.org\/10.3389\/fgene.2023.1269291.","journal-title":"J Clin Lipidol"},{"key":"865_CR49","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.1016\/j.molmet.2025.102137","volume":"13","author":"Z Feng","year":"2022","unstructured":"Ni D, Qi Z, Ma S, Wang Y, Liang D, Zhang X, et al. Membrane-associated ring\u2013CH\u2013type finger 2 protects against metabolic dysfunction-associated fatty liver disease by targeting fatty acid synthase. Mol Metab. 2025;96:102137. https:\/\/doi.org\/10.1016\/j.molmet.2025.102137.","journal-title":"Front Pharmacol"},{"issue":"20","key":"865_CR50","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/advs.201900739","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Liu C, Zhao H, Xiao S, Han T, Chen Y, Wang T, et al. Slx5p-Slx8p promotes accurate chromosome segregation by mediating the degradation of synaptonemal complex components during meiosis. Adv Sci (Weinh Baden-Wurtt Ger). 2020;7:1900739. https:\/\/doi.org\/10.1002\/advs.201900739.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"865_CR51","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.70389\/PJS.100082","volume":"82","author":"RS Wright","year":"2023","unstructured":"Agha R, Mathew G, Rashid R, Kerwan A, Al-Jabir A, Sohrabi C, et al. Transparency in the reporting of artificial INtelligence \u2013 the TITAN guideline. PJS. 2025. https:\/\/doi.org\/10.70389\/PJS.100082.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"865_CR52","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1371\/journal.pbio.1000412","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLOS Biol. 2010;8:e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412.","journal-title":"Can J Cardiol"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00865-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00865-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00865-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:28:24Z","timestamp":1788485304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00865-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00865-6","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"165"}}